This results in reduced expression of cholinergic markers, including choline acetyltransferase (ChAT) and vesicular acetylcholine transporter (VAChT), contributing to cognitive deficits characteristic of the disease (Figure 1). Here, SLC18A3 is linked to Cognitive impairment.